Novel Therapeutic Strategies for Delirium in Patients With Cancer
| Autor: | Hiroshi Tsujimoto, Shinichiro Nakajima, Isseki Maeda, Madoka Tokuyama, Hitoshi Tanimukai, Yoshiaki Okamoto, Sho Goya, Yoshinobu Matsuda, Motoo Watanabe, Toshihiro Taira, Seitetsu Kanemura, Toshihiro Kai, Kiyozumi Takei, Akihiro Tokoro, Ichiro Tsujio, Yujiro Kashiwagi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Olanzapine medicine.medical_specialty Severity of Illness Index Benzodiazepines Quetiapine Fumarate 03 medical and health sciences 0302 clinical medicine Rating scale Neoplasms Internal medicine medicine Haloperidol Humans In patient 030212 general & internal medicine Psychiatry Aged Aged 80 and over Risperidone business.industry Delirium Cancer General Medicine Middle Aged medicine.disease Cross-Sectional Studies Quetiapine Female medicine.symptom business 030217 neurology & neurosurgery Antipsychotic Agents Half-Life medicine.drug |
| Zdroj: | American Journal of Hospice and Palliative Medicine®. 33:456-462 |
| ISSN: | 1938-2715 1049-9091 |
| Popis: | To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS). The symptom severity was evaluated by the memorial delirium rating scale (MDAS) on days 0, 3, and 7 following intervention. Significant improvements in total MDAS scores were found in all groups on day 3. However, on day 7, only the short T1/2 group and MARTA group showed significant improvement. Consideration of an AP’s pharmacological properties may be helpful for improving the outcomes of pharmacological delirium intervention in patients with cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|